This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...
Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
Despite strong cash flow and organic growth in most of its key brands, high leverage and mixed valuation ratios lead to a ...
GSK plans to invest $800 million in its East Donegal Township vaccine packaging facility over the next four years in an ...
The allergy treatment market is set to experience robust growth, with an estimated valuation of US$ 20.20 billion in 2022 and ...
GSK has announced a new collaboration with local university and medical researchers, while Editas Medicine has a deal to ...
GSK is presenting its case for broader use of its RSV vaccine with new data from a pair of studies in younger adults with ...
Hosted on MSN22h
GSK’s Arexvy Vaccine Shows Promise for Broader UseGlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...
The projected market expansion presents a unique opportunity for stakeholders to invest in and prioritize the development of ...
North Carolina is a leading place for biotech, and a big part of that success comes from GlaxoSmithKline (GSK). This global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback